Previously, we developed a quantitative measurement system for plasma oxidative stress using Cys34-cysteinylated albumin (oxidized albumin) (Nagumo et al, 2014; Watanabe et al, 2017), which is also clinically useful as a biomarker for the progression of kidney diseases (Imafuku et al, 2021). This evidence concerns the gene ALB and kidney disorder.